Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae890 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Dalal S Ali und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, McMaster University, Hamilton, ON, Canada L8S 4L8. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: McMaster University.
Abstract (Originalsprache)
Context
Understanding the effects of burosumab compared to conventional therapy or no treatment on patient-important outcomes in adults with X-linked hypophosphatemia (XLH) is essential to guide evidence-based treatment recommendations.
Objective
To examine the highest certainty evidence addressing the management of XLH in adults to inform treatment recommendations.
Methods
We searched Embase, MEDLINE, Web of Science, and Cochrane Central up to May 2023. Eligible studies included randomized controlled trials (RCTs) and observational studies of individuals aged 18+ with clinically or genetically confirmed XLH. Manuscripts comparing burosumab to no treatment or conventional therapy (phosphate and active vitamin D) and conventional therapy to no treatment were included. Two reviewers independently determined eligibility, extracted data, and assessed risk of bias (RoB). GRADE methodology was used to assess evidence certainty.
Results
We screened 4114 records, after removing duplicates, and assessed 254 full texts. One RCT and 2 observational studies were eligible. The RCT of burosumab vs no treatment had low RoB. Burosumab probably improves pain from fracture/pseudofracture healing (moderate certainty) but has little or no impact on direct pain measures (moderate certainty). Burosumab may reduce the need for parathyroidectomy (low certainty) but has little or no impact on fatigue (high certainty), stiffness (moderate certainty), and mobility (low certainty) over 24 weeks. Burosumab may increase dental abscess risk (low certainty). Indirect evidence comparing burosumab to conventional therapy provided low certainty regarding burosumab vs conventional therapy. Two observational studies on conventional therapy vs no treatment had high RoB and very low certainty regarding the impact of conventional therapy on patient-important outcomes.
Conclusion
No formal comparisons between burosumab and conventional therapy in adults exist. Evidence for conventional therapy vs no treatment is very uncertain. Our review highlights the need for more data on the long-term effects of burosumab and conventional therapy on patient-important outcomes in adult patients with XLH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, McMaster University, Hamilton, ON, Canada L8S 4L8.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada L8S 4L8.
- Department of Internal Medicine, Division of Endocrinology, Center for Bone Quality, Leiden University Medical Center, 2300 ZA Leiden, the Netherlands.
- Centre for Rare Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark.
- Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark.
- Department of Oral Medicine, Faculty of Dentistry, UMR 1333, Inserm and APHP, Université Paris Cité, 75006 Paris, France.
ORCID-Profile: Dalal S Ali, Reza D Mirza, Farah Alsarraf, Salma Hussein, Hajar Abu Alrob, Natasha M Appelman-Dijkstra, Signe Sparre Beck-Nielsen, Martin Biosse-Duplan, Maria Luisa Brandi, Thomas O Carpenter, Catherine Chaussain, Martine Cohen-Solal, Rachel K Crowley, Karel Dandurand, Pablo Florenzano, Seiji Fukumoto, Claudia Gagnon, Paul Goodyer, Corinna Grasemann, Erik A Imel, Suzanne M Jan de Beur, Anna Lehman, E Michael Lewiecki, Emmett Morgante, Leanne M Ward, Aliya A Khan, Gordon Guyatt
Förderung
- McMaster University
Zitieren
APA
Ali, D. S., Mirza, R. D., Alsarraf, F., Hussein, S., Abu Alrob, H., Appelman-Dijkstra, N. M., Beck-Nielsen, S. S., Biosse-Duplan, M., Brandi, M. L., Carpenter, T. O., Chaussain, C., Cohen-Solal, M., Crowley, R. K., Dandurand, K., Florenzano, P., Fukumoto, S., Gagnon, C., Goodyer, P., Grasemann, C., …, & Guyatt, G. (2025). Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae890
Vancouver
Ali DS, Mirza RD, Alsarraf F, Hussein S, Abu Alrob H, Appelman-Dijkstra NM, et al. Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae890
BibTeX
@article{Ali2025,
author = {Ali, Dalal S and Mirza, Reza D and Alsarraf, Farah and Hussein, Salma and Abu Alrob, Hajar and Appelman-Dijkstra, Natasha M and Beck-Nielsen, Signe Sparre and Biosse-Duplan, Martin and Brandi, Maria Luisa and Carpenter, Thomas O and Chaussain, Catherine and Cohen-Solal, Martine and Crowley, Rachel K and Dandurand, Karel and Florenzano, Pablo and Fukumoto, Seiji and Gagnon, Claudia and Goodyer, Paul and Grasemann, Corinna and Imel, Erik A and Jan de Beur, Suzanne M and Lehman, Anna and Lewiecki, E Michael and Morgante, Emmett and Ward, Leanne M and Khan, Aliya A and Guyatt, Gordon},
title = {Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae890}
}
EUVIMED